Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

Currently available antidepressants may aggravate sexual dysfunction and make depression worse, a new survey of US adults with major depressive disorder (MDD) suggests.

Mental Health Survey Reveals Available Antidepressants Aggravate Sexual Dysfunction and Make Depression Worse

FDA Rules Favorably On Efficacy Of Travivo™ (Gepirone ER) For Treatment Of Major Depressive Disorder

Fabre-Kramer Looks Forward to FDA’s Decision on Gepirone ER for the Treatment of Major Depressive Disorder